keyword
MENU ▼
Read by QxMD icon Read
search

ovarian biomarkers

keyword
https://www.readbyqxmd.com/read/29240605/platelet-derived-growth-factor-d-is-a-prognostic-biomarker-and-is-associated-with-platinum-resistance-in-epithelial-ovarian-cancer
#1
Mengjun Zhang, Tianbo Liu, Bairong Xia, Chunyan Yang, Siyu Hou, Wanlin Xie, Ge Lou
OBJECTIVE: This study aimed to investigate whether platelet-derived growth factor D (PDGF-D) is a prognostic biomarker and is associated with platinum resistance in epithelial ovarian cancer, which has not been studied by others previously. METHODS: In this study, we detected expression of PDGF-D in ovarian cancer tissues through immunohistochemistry and Western blotting. Furthermore, we analyzed the association between PDGF-D expression and clinicopathological features including prognosis in epithelial ovarian cancer...
December 13, 2017: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/29240604/potential-significance-of-peptidome-in-human-ovarian-cancer-for-patients-with-ascites
#2
Xiaohao Huang, Juan Zhou, Ranran Tang, Suping Han, Xue Zhou
OBJECTIVE: Ovarian cancer (OC) is one of the lethal gynecological malignancies. Most women affected by OC with malignant ascites will relapse. Peptidomics, as an emerging branch of proteomics, is more applied in screening of disease biomarkers, diagnosis, treatment, and monitoring. However, there is still little in-depth analysis about peptidomics study in OC with malignant ascites. METHODS: A comparative peptidomic profiling of ascites fluid between 6 OC patients and 6 benign gynecological conditions using liquid chromatography-tandem mass spectrometry was analyzed...
December 13, 2017: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/29238349/the-roles-of-glycodelin-in-cancer-development-and-progression
#3
REVIEW
Juan Cui, Yanguo Liu, Xiuwen Wang
Glycodelin is a kind of glycoprotein expressed in secretory endometrium, pregnancy deciduas, and amniotic fluid originally, which is vital for the maintenance of normal human reproductive activities. Recent researches have reported that glycodelin is specifically expressed in various malignancies, including female-specific cancers such as endometrial cancer, ovarian cancer and breast cancer, and non-gender specific cancers including lung cancer, and colon cancer, and glycodelin expression correlates with the diagnosis and prognosis of cancer patients...
2017: Frontiers in Immunology
https://www.readbyqxmd.com/read/29238081/pyridoxine-5-phosphate-oxidase-is-a-novel-therapeutic-target-and-regulated-by-the-tgf-%C3%AE-signalling-pathway-in-epithelial-ovarian-cancer
#4
Lingyun Zhang, Daibing Zhou, Wencai Guan, Weimin Ren, Wenwen Sun, Jimin Shi, Qunbo Lin, Jinguo Zhang, Tiankui Qiao, Yulong Ye, Yun Wu, Yaning Zhang, Xulei Zuo, Kristin L Connor, Guoxiong Xu
Pyridoxine 5'-phosphate oxidase (PNPO) is an enzyme that converts pyridoxine 5'-phosphate into pyridoxal 5'-phosphate (PLP), an active form of vitamin B6 implicated in several types of cancer. However, the role of PNPO and its regulatory mechanism in epithelial ovarian cancer (EOC) are unknown. In the present study, PNPO expression in human ovarian tumour tissue and its association with the clinicopathological features of patients with EOC were examined. Further, the biological function of PNPO in EOC cells and in xenograft was evaluated...
December 13, 2017: Cell Death & Disease
https://www.readbyqxmd.com/read/29233504/the-utility-of-anti-m%C3%A3-llerian-hormone-in-women-with-chronic-kidney-disease-on-haemodialysis-and-after-kidney-transplantation
#5
Sokratis Stoumpos, Jennifer Lees, Paul Welsh, Martin Hund, Colin C Geddes, Scott M Nelson, Patrick B Mark
Women with renal disease have menstrual and gonadal dysfunction manifesting as hormonal imbalance. Anti-Müllerian hormone (AMH) is a potential measure of ovarian reserve. We examined circulating AMH concentrations in young women with renal failure, determined associations with clinical characteristics, and compared AMH with age-matched healthy individuals. AMH was measured in 77 women: 26 had chronic kidney disease (CKD), 26 were on haemodialysis (HD), and 25 had a kidney transplant. Random AMH levels were highest in women on HD [HD 2...
November 28, 2017: Reproductive Biomedicine Online
https://www.readbyqxmd.com/read/29232474/is-intraperitoneal-chemotherapy-still-an-acceptable-option-in-primary-adjuvant-chemotherapy-for-advanced-ovarian-cancer
#6
B J Monk, J K Chan
The role of intraperitoneal (i.p.) chemotherapy in treating newly diagnosed advanced epithelial ovarian cancer (EOC) has been the subject of controversy for almost three decades. Three large intergroup phase III trials (GOG 104, 114, 172) have demonstrated a survival benefit associated with i.p. over intravenous (i.v.) therapy in advanced, low-volume EOC. Despite the positive clinical trial results and a subsequent National Cancer Institute alert in 2006, i.p. treatment has not been widely accepted as the standard of care in the United States and is infrequently used in Europe...
November 1, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29232470/how-can-molecular-abnormalities-influence-our-clinical-approach
#7
W Wei, F Giulia, S Luffer, R Kumar, B Wu, M Tavallai, R T Bekele, M J Birrer
Background: Despite improvements in diagnostics and treatment, the clinical outcome of epithelial ovarian cancer remains poor over the last three decades. Recent high-throughput genomic studies have demonstrated ovarian cancer as a highly heterogeneous entity with distinctive molecular signatures among different or even within the same histotype. In this article, we review the molecular genetics of epithelial ovarian cancer and how they have been translated into modern clinical trials, as well as their implications in patient stratification for more targeted and personalized approaches...
November 1, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29232469/acquired-chemotherapy-resistance-in-ovarian-cancer
#8
E L Christie, D D L Bowtell
Most women diagnosed with high-grade serous ovarian cancer (HGSC) develop recurrent disease and chemotherapy resistance, despite initially responding to treatment. The genomic characteristics of HGSC samples collected at initial surgery have been extensively studied. However, due to challenges of sample collection following treatment, much less is known about the molecular features of recurrent disease. Our recent studies have identified mechanisms of acquired resistance and biomarkers in recurrent HGSCs that could lead to improved treatment approaches...
November 1, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29232467/immunotherapy-in-ovarian-cancer
#9
K Odunsi
Immunological destruction of tumors is a multistep, coordinated process that can be modulated or targeted at several critical points to elicit tumor rejection. These steps in the cancer immunity cycle include: (i) generation of sufficient numbers of effector T cells with high avidity recognition of tumor antigens in vivo; (ii) trafficking and infiltration into the tumor; (iii) overcoming inhibitory networks in the tumor microenvironment; (iv) direct recognition of tumor antigens and generation of an effector anti-tumor response; and (v) persistence of the anti-tumor T cells...
November 1, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29231068/clinicopathological-and-prognostic-significance-of-platelet-count-in-patients-with-ovarian-cancer
#10
Q Zhou, F Huang, Z He, M-Z Zuo
AIM: Increasing evidence indicates that platelet count is a useful biomarker of long-term outcomes in patients with ovarian cancer. However, the prognostic value of platelet count in patients with ovarian cancer remains controversial. We therefore conducted a meta-analysis aimed to investigate the prognostic role of the platelet count in patients with ovarian cancer. METHOD: A comprehensive search was performed from the databases of PubMed, Embase and the Cochrane Library until June 20, 2017...
December 12, 2017: Climacteric: the Journal of the International Menopause Society
https://www.readbyqxmd.com/read/29228656/increased-pdgfr-beta-and-vegfr-2-protein-levels-are-associated-with-resistance-to-platinum-based-chemotherapy-and-adverse-outcome-of-ovarian-cancer-patients
#11
Stefanie Avril, Yasemin Dincer, Katharina Malinowsky, Claudia Wolff, Sibylle Gündisch, Alexander Hapfelmeier, Melanie Boxberg, Holger Bronger, Karl-Friedrich Becker, Barbara Schmalfeldt
Despite frequent initial response rates of epithelial ovarian cancer to platinum-based chemotherapy the majority of patients develop drug resistance. Our aim was to evaluate differential expression of signaling-pathway proteins in platinum-sensitive versus platinum-resistant primary epithelial ovarian cancer specimens to identify predictive biomarkers for treatment response. 192 patients were studied comprising of independent training (n = 89) and validation (n = 103) cohorts. Full-length proteins were extracted from paraffin-embedded samples including multiple regions per tumor to account for intratumoral heterogeneity...
November 17, 2017: Oncotarget
https://www.readbyqxmd.com/read/29224849/aptamers-as-potential-therapeutic-agents-for-ovarian-cancer
#12
REVIEW
Justin Liam Henri, Joanna Macdonald, Mia Strom, Wei Duan, Sarah Shigdar
Current therapy for ovarian cancer typically involves indiscriminate chemotherapies that can have severe off target effects on healthy tissue and are still plagued by aggressive recurrence. Recent shifts towards targeted therapies offer the possibility of circumventing the obstacles experienced by these traditional treatments. While antibodies are the pioneering agents in targeted therapies, clinical experience has demonstrated that their antitumor efficacy is limited due to their high immunogenicity, large molecular size, and costly and laborious production...
December 7, 2017: Biochimie
https://www.readbyqxmd.com/read/29222021/identification-and-validation-of-salivary-proteomic-signatures-for-non-invasive-detection-of-ovarian-cancer
#13
Md Tajmul, Farhat Parween, Lata Singh, Sandeep R Mathur, J B Sharma, Sunesh Kumar, D N Sharma, Savita Yadav
Ovarian cancer (OC) is one of the most lethal cancers among all gynecological malignancies. An effective and non-invasive screening approach is needed urgently to reduce high mortality rate. The purpose of this study was to identify the salivary protein signatures (SPS) for non-invasive detection of ovarian cancer. Differentially expressed SPS were identified by fluorescence-based 2D-DIGE coupled with MALDI/TOF-MS. The expression levels of three differential proteins (Lipocalin-2, indoleamine-2, 3-dioxygenase1 (IDO1) and S100A8) were validated using western blotting and ELISA...
December 5, 2017: International Journal of Biological Macromolecules
https://www.readbyqxmd.com/read/29218693/non-catalytic-region-of-tyrosine-kinase-adaptor-protein-2-nck2-pathways-as-factor-promoting-aggressiveness-in-ovarian-cancer
#14
Mara Fanelli, Alessia Camperchioli, Lella Petrella, Marco Petrillo, Cinzia Baranello, Pina Baccaro, Carmela Paolillo, Ettore Capoluongo, Giovanni Scambia
BACKGROUND: In this study we investigated the function of the non-catalytic region of tyrosine kinase adaptor protein 2 (NCK2) and its correlation with ITGB1 and ITGB4 integrins in driving ovarian cancer (OvCa) aggressiveness. We also evaluated whether NCK2 may influence prognosis in OvCa patients. METHODS: Nanofluidic technology was used to analyze expression of NCK2 in 332 OvCa patients. To evaluate mRNA expression of NCK2, integrins and VEGFA in OvCa cell lines, qRT-PCR was performed...
December 5, 2017: International Journal of Biological Markers
https://www.readbyqxmd.com/read/29214776/14-3-3%C3%AE-overexpression-is-associated-with-poor-prognosis-in-ovarian-cancer
#15
Hyun Jung Kim, Sun Hee Sung, Chan Young Kim, Moon Kyoung Bae, Min Sun Cho, Yun Hwan Kim, Seung Cheol Kim, Woong Ju
PURPOSE: 14-3-3ζregulates cell signaling, cell cycle progression, and apoptosis, and its overexpression is associated with disease recurrence and poor clinical outcomes in some solid tumors. However, its clinicopathological role in ovarian cancer is unknown. Our goal was to investigate whether 14-3-3ζis associated with ovarian cancer prognosis. MATERIALS AND METHODS: We examined 14-3-3ζexpression by immunohistochemistry in ovarian cancer tissues obtained from 88 ovarian cancer patients...
January 2018: Yonsei Medical Journal
https://www.readbyqxmd.com/read/29212506/chromosome-9p-copy-number-gains-involving-pd-l1-are-associated-with-a-specific-proliferation-and-immune-modulating-gene-expression-program-active-across-major-cancer-types
#16
Jan Budczies, Carsten Denkert, Balázs Győrffy, Peter Schirmacher, Albrecht Stenzinger
BACKGROUND: Inhibition of the PD-L1/PD-1 immune checkpoint axis represents one of the most promising approaches of immunotherapy for various cancer types. However, immune checkpoint inhibition is successful only in subpopulations of patients emphasizing the need for powerful biomarkers that adequately reflect the complex interaction between the tumor and the immune system. Recently, recurrent copy number gains (CNG) in chromosome 9p involving PD-L1 were detected in many cancer types including lung cancer, melanoma, bladder cancer, head and neck cancer, cervical cancer, soft tissue sarcoma, prostate cancer, gastric cancer, ovarian cancer, and triple-negative breast cancer...
December 6, 2017: BMC Medical Genomics
https://www.readbyqxmd.com/read/29207246/multiple-reaction-monitoring-for-the-quantitation-of-serum-protein-glycosylation-profiles-application-to-ovarian-cancer
#17
Suzanne Miyamoto, Carol D Stroble, Sandra Taylor, Qiuting Hong, Carlito B Lebrilla, Gary S Leiserowitz, Kyoungmi Kim, L Renee Ruhaak
Protein glycosylation fingerprints are widely recognized as potential markers for disease states and indeed differential glycosylation has been identified in multiple types of autoimmune diseases and several types of cancer. However, releasing the glycans leave the glycoproteins unknown, therefore there exists a need for high-throughput methods that allow quantification of site- and protein- specific glycosylation patterns from complex biological mixtures. In this study, a targeted multiple reaction monitoring (MRM)-based method for the protein- and site- specific quantitation involving serum proteins immunoglobulins A, G and M, alpha-1-antitrypsin, transferrin, alpha-2-macroglobulin, haptoglobin, alpha-1-acid glycoprotein and complement C3 was developed...
December 5, 2017: Journal of Proteome Research
https://www.readbyqxmd.com/read/29205122/parp-inhibitors-in-epithelial-ovarian-cancer
#18
Kristin N Taylor, Ramez N Eskander
Background Ovarian cancer remains the most common lethal gynecologic malignancy. The therapeutic gains with use of traditional cytotoxic chemotherapy in advanced stage disease remain limited, reflecting the need for novel therapies. Poly(ADP-ribose) polymerase (PARP) inhibitors have recently demonstrated a significant therapeutic effect in patients with recurrent, high grade serous ovarian cancer, both in the treatment of existing disease and in prolonging the disease-free interval. Objective The purpose of this article is to discuss PARP inhibitor use in patients with advanced stage ovarian cancer, and to extensively review the existing clinical literature and related patents...
December 3, 2017: Recent Patents on Anti-cancer Drug Discovery
https://www.readbyqxmd.com/read/29203663/selected-reaction-monitoring-approach-for-validating-peptide-biomarkers
#19
Qing Wang, Ming Zhang, Tyler Tomita, Joshua T Vogelstein, Shibin Zhou, Nickolas Papadopoulos, Kenneth W Kinzler, Bert Vogelstein
We here describe a selected reaction monitoring (SRM)-based approach for the discovery and validation of peptide biomarkers for cancer. The first stage of this approach is the direct identification of candidate peptides through comparison of proteolytic peptides derived from the plasma of cancer patients or healthy individuals. Several hundred candidate peptides were identified through this method, providing challenges for choosing and validating the small number of peptides that might prove diagnostically useful...
December 4, 2017: Proceedings of the National Academy of Sciences of the United States of America
https://www.readbyqxmd.com/read/29194839/analysis-of-the-ectoenzymes-ada-alp-enpp1-and-enpp3-in-the-contents-of-ovarian-endometriomas-as-candidate-biomarkers-of-endometriosis
#20
Carla Trapero, Lluis Jover, Maria Eulàlia Fernández-Montolí, Amparo García-Tejedor, August Vidal, Inmaculada Gómez de Aranda, Jordi Ponce, Xavier Matias-Guiu, Mireia Martín-Satué
PROBLEM: The diagnosis of endometriosis, a prevalent chronic disease with a strong inflammatory component, is usually delayed due to the lack of noninvasive diagnostic tests. Purinergic signaling, a key cell pathway, is altered in many inflammatory disorders. The aim of the present work was to evaluate the levels of adenosine deaminase (ADA), alkaline phosphatase (ALP), ecto-nucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), and ENPP3, elements of purinergic signaling, as biomarker candidates for endometriosis...
November 30, 2017: American Journal of Reproductive Immunology: AJRI
keyword
keyword
120394
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"